Results 81 to 90 of about 51,615 (305)

Why We Do Not Recommend That People With High‐Risk Smoldering Myeloma Receive Treatment

American Journal of Hematology, EarlyView.
Ghulam Rehman Mohyuddin, Mackenzie Lemieux, Rajshekhar Chakraborty, Morie Gertz   +3 more
wiley   +1 more source

Population Pharmacokinetics and Exposure–Response Analyses of Momelotinib, Its Active Metabolite (M21), and Total Active Moiety in Myelofibrosis

Clinical Pharmacology &Therapeutics, EarlyView.
Momelotinib, a Janus kinase (JAK) 1/JAK2/activin A receptor type 1 inhibitor, is approved for the treatment of myelofibrosis with anemia. These analyses characterized the population pharmacokinetics of momelotinib and its active metabolite M21 following administration of the commercial tablet formulation in patients with myelofibrosis from phase II/III
Benjamin Rich, Meenakshi Srinivasan, Yu Liu Ho, Sandra A.G. Visser, Geraldine Ferron‐Brady, Georgios Vlasakakis   +5 more
wiley   +1 more source

Lenalidomide for the Treatment of Low- or Intermediate-1-Risk Myelodysplastic Syndromes Associated with Deletion 5q Cytogenetic Abnormality: An Evidence Review of the NICE Submission from Celgene [PDF]

, 2015
The National Institute for Health and Care Excellence (NICE) invited the manufacturer of lenalidomide (Celgene) to submit evidence of the clinical and cost effectiveness of the drug for treating adults with myelodysplastic syndromes (MDS) associated with
Al, M.J. (Maiwenn), Armstrong, N. (Nigel), Blommestein, H.M. (Hedwig), Deshpande, S. (Sohan), Kleijnen, J.M.P. (Jos), Noake, C. (Caro), Riemsma, R. (Rob), Ryder, S. (Steve), Severens, J.L. (Hans), Worthy, G. (Gill)   +9 more
core   +5 more sources

Cystatin C‐based eGFR better predicts renal vancomycin clearance than creatinine‐based eGFR in patients with allogeneic stem cell transplantation

Clinical Pharmacology &Therapeutics, EarlyView.
Knowledge of the glomerular filtration rate (GFR) is mandatory when dosing renally eliminated drugs such as vancomycin. In clinical practice, different biomarkers and various equations are used to estimate GFR (eGFR), resulting in varying estimates.
Eva‐Maria A. Wansing, Sebastian G. Wicha, Peter Bannas, Alexander Heitkamp, Adrin Dadkhah, Nicolaus M. Kröger, Isabel Molwitz, Claudia Langebrake   +7 more
wiley   +1 more source

Myelodysplastic syndromes: Classification

Journal of Applied Hematology, 2014
The updated WHO classification system for myelodysplastic syndromes (MDS) includes some new entities, in particular "refractory cytopenias with unilineage dysplasia (RCUD)". The following review article presents a short overview regarding all subvariants
Hans Peter Horny
doaj   +1 more source

A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with less than or equal to 30% blasts [PDF]

, 2017
Treatment with azacitidine (AZA), a demethylating agent, prolonged overall survival (OS) vs conventional care in patients with higher-risk myelodysplastic syndromes (MDS). As median survival with monotherapy is
AM Zeidan, AO Soriano, BD Cheson, BD Cheson, CJ Clopper, D Merkel, DJ DeAngelo, E Raffoux, G Garcia-Manero, G Garcia-Manero, G Garcia-Manero, H Dombret, H Khan, J Babb, JP Issa, JP Issa, JP Laubach, L Maurillo, L Pleyer, M Kirschbaum, M Lubbert, Mikkael A. Sekeres, P Atadja, P Fenaux, P Fenaux, P Maslak, P Tan, PG Richardson, SD Gore, SD Nimer, T Prebet, TE Fandy, W Blum, W Fiskus, Y Ofran, YG Lee   +35 more
core   +2 more sources

Monocyte maturation pattern by flow cytometry expression of CD64, CD300e, and CD14 correlates to presence of myeloid neoplasm and helps identify blast equivalents in the setting of monocytic neoplasm

Cytometry Part B: Clinical Cytometry, EarlyView.
Abstract CD300e is a marker of mature monocytes in flow cytometry; however, there is limited detailed information on staining patterns in conjunction with other monocyte markers. We evaluated the flow cytometric staining patterns of CD64, CD14, and CD300e in 12 negative and 33 positive peripheral blood specimens and 16 negative and 56 positive bone ...
Jenny Zhang, Jacob Kaplan, Elizabeth Courville   +2 more
wiley   +1 more source

Recombinant human erythropoietin plus all-trans retinoic acid and testosterone undecanoate for the treatment of anemia in patients with lower-risk myelodysplastic syndromes: a multicenter, single-arm, prospective trial

Haematologica
Erythropoiesis-stimulating agents (ESAs) achieve hematological improvement-erythroid (HIE) in only 30% of ESA-naïve lower risk myelodysplastic syndrome (LR-MDS) patients with anemia, highlighting the need for developing novel drugs or new treatment ...
Chen Mei, Gaixiang Xu, Cuiping Zheng, Yaping Xie, Minming Li, Yanping Shao, Rongxin Yao, Shi Tao, Wei Jiang, Jun Guo, Zhiyin Zheng, Wei Wang, Xinping Zhou, Liya Ma, Li Ye, Yingwan Luo, Chunmei Yang, Wenjuan Yu, Wanzhuo Xie, Jie Jin, Hongyan Tong   +20 more
doaj   +1 more source

Rare occurrence of DNMT3A mutations in myelodysplastic syndromes

Haematologica, 2011
Gene mutations and epigenetic changes have been shown to play significant roles in the pathogenesis of myelodysplastic syndromes. Recently, mutations in DNMT3A were identified in 22.1% of patients with acute myeloid leukemia.
Felicitas Thol, Claudia Winschel, Andrea Lüdeking, Haiyang Yun, Inna Friesen, Frederik Damm, Katharina Wagner, Jürgen Krauter, Michael Heuser, Arnold Ganser   +9 more
doaj   +1 more source

Stem cell factor SALL4, a potential prognostic marker for myelodysplastic syndromes [PDF]

, 2013
Background: Myelodysplastic syndromes (MDS) are a group of heterogeneous diseases with variable clinical course. Predicting disease progression is difficult due to lack of specific molecular marker(s).
Chai, Li, Chen, Qian, Cui, Wei, Guo, Ye, Ning, Ning, Tong, Chunrong, Wang, Fei, Xu, Xiaodong, Xu, Yonggang, Yang, Zhuo, Zhang, Yujuan   +10 more
core   +3 more sources